WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address ...
Aileron Therapeutics' Phase 1b trial of inhaled LTI-03 showed positive trends in seven out of eight IPF biomarkers. LTI-03 reduced SPD by 5% at 14 days, outperforming current IPF standard care's 4% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback